Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Product/Service, Webcast

Terns Pharmaceuticals to Present Clinical Data on Improved TERN-101 Tablet Formulation at the Paris NASH Digital Experience


Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing best-in-class single-agent and combination therapies to treat non-alcoholic steatohepatitis (NASH) and other liver diseases, announced today the presentation of new clinical data on an improved tablet formulation of its liver-distributed farnesoid X receptor (FXR) agonist TERN-101 at the Paris NASH Digital Experience, taking place virtually October 22-23, 2020. The presentation, entitled "Comparative pharmacokinetics of two oral formulations of nonsteroidal farnesoid X receptor agonist TERN-101 in healthy volunteers," demonstrated that an amorphous tablet formulation of TERN-101, which is currently being evaluated in the Phase 2a LIFT study in NASH patients, achieved faster absorption and higher plasma levels compared to a previous crystalline capsule formulation of TERN-101. The study results also demonstrate that the new formulation reduces pharmacokinetic variability and that TERN-101 can be administered without regard to food.

"In Terns' Phase 1 studies, TERN-101 has demonstrated potent FXR activation in the liver and is well tolerated, with no observation of pruritus and no difference from placebo in serum lipid effects. We've now developed an improved formulation that optimizes absorption and minimizes PK variability," said Erin Quirk, M.D., President and Chief Medical Officer of Terns. "This new TERN-101 formulation is now being studied in our 12-week Phase 2a LIFT study in NASH patients, and we look forward to seeing the results in mid-2021."

Full details from the presentation can be found at www.ternspharma.com/scientific-publications.

About TERN-101 and Farnesoid X Receptor (FXR) Agonism

TERN-101 is a potent, non-steroidal FXR agonist, with enhanced liver distribution being developed for the treatment of NASH. FXR is a nuclear receptor that is highly expressed in the liver and small intestine. FXR agonism has demonstrated improvement over placebo in regression of histological liver fibrosis without progression of NASH in a late-stage study, demonstrating the potential for FXR agonists to be a new treatment modality for NASH. TERN-101 has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) for the treatment of NASH.

About NASH

Non-alcoholic steatohepatitis (NASH) is a severe form of non-alcoholic fatty liver disease (NAFLD), which is caused by the accumulation of excess fat in the liver. NASH is associated with chronic liver inflammation and liver cell injury, and it can lead to fibrosis, cirrhosis, and eventually liver cancer or liver failure. Global rates of NAFLD and NASH are increasing rapidly, in tandem with rising rates of obesity. There is currently no approved medication for the treatment of NASH.

About Terns Pharmaceuticals

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing best-in-class single-agent and combination therapies to treat non-alcoholic steatohepatitis (NASH) and other liver diseases. The company's liver-selective FXR-agonist, TERN-101, is currently conducting a multi-center, randomized, double-blind, placebo-controlled Phase 2a clinical trial designed to evaluate efficacy, safety, and pharmacokinetics in 96 presumed NASH patients who receive placebo or TERN-101 at various dose levels for 12 weeks. Terns recently announced positive Phase 1 clinical data for its highly selective SSAO inhibitor, TERN-201, demonstrating potent and sustained target engagement. In addition, the company is actively planning to initiate clinical studies for its thyroid hormone receptor beta agonist TERN-501 as monotherapy and in combination with its other pipeline assets for NASH, as well as advancing its small molecule GLP-1R agonist program. Terns' investors include OrbiMed, Vivo Capital, Lilly Asia Ventures, and Decheng Capital.


These press releases may also interest you

at 09:00
? R&D activities focused on advancing the development of innovative delivery systems and yeast beta glucan as a potential inhalable therapeutic for COVID-19 ? ? Q3 2020 sales of $3,476,000 compared to $2,908,000 for Q3 2019, representing a 20%...

at 09:00
The "2020 United States Home Gym Equipment Market" report has been added to ResearchAndMarkets.com's offering. A comprehensive analysis of the United States Home Gym Equipment Market which includes market sizing, market share by competitor, drivers,...

at 09:00
Ziegler, a specialty investment bank, is pleased to announce its role in advising CareFirst BlueCross BlueShield (CareFirst) in the acquisition of University of Maryland Health Partners (UMHP) and University of Maryland Health Advantage (UMHA) from...

at 08:36
Suraksha Naturals has been tapping into a burgeoning aspect of the supplemental health industry with their natural sprayable supplements that are made utilizing Ayurvedic herbs. Suraksha Natural's goal with their Keto-Veyda product line has been to...

at 08:30
The "Global Neurorehabilitation Device Market 2019-2028" report has been added to ResearchAndMarkets.com's offering. The publisher, in its research report, estimates the global neurorehabilitation device market to proliferate with a CAGR of 14.52%...

at 08:05
4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome, today announces the filing of a registration statement on Form F-4 (the...



News published on 22 october 2020 at 05:05 and distributed by: